Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · IEX Real-Time Price · USD
4.070
+0.140 (3.56%)
At close: Apr 26, 2024, 4:00 PM
3.970
-0.100 (-2.46%)
After-hours: Apr 26, 2024, 7:59 PM EDT
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for AQST stock have an average target of 8.83, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 116.95% from the current stock price of 4.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AQST stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $10 | Buy | Initiates | $10 | +145.70% | Apr 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +121.13% | Apr 5, 2024 |
| Raymond James | Raymond James | Buy Initiates $7 | Buy | Initiates | $7 | +71.99% | Mar 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $9 | Strong Buy | Maintains | $7 → $9 | +121.13% | Mar 18, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +145.70% | Mar 15, 2024 |
Financial Forecast
Revenue This Year
51.22M
from 50.58M
Increased by 1.26%
Revenue Next Year
59.31M
from 51.22M
Increased by 15.79%
EPS This Year
-0.36
from -0.13
EPS Next Year
-0.31
from -0.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 54.6M | 80.9M | 102.3M | 108.8M | 152.2M |
| Avg | 51.2M | 59.3M | 87.9M | 105.7M | 147.8M |
| Low | 47.1M | 48.8M | 73.5M | 101.6M | 142.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 7.9% | 57.8% | 72.4% | 23.8% | 43.9% |
| Avg | 1.3% | 15.8% | 48.3% | 20.2% | 39.8% |
| Low | -6.8% | -4.7% | 23.9% | 15.5% | 34.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.29 | -0.13 | 0.09 |
| Avg | -0.36 | -0.31 | -0.05 |
| Low | -0.44 | -0.46 | -0.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.